Research
Hormonal
GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) by 14% and all-cause mortality by 12% in patients with type 2 diabetes.
If you have Type 2 Diabetes and are at high risk for heart disease, ask your doctor about GLP-1 receptor agonists (like liraglutide or semaglutide). These medications have been shown to significantly reduce the risk of heart attacks, strokes, and death, in addition to helping with blood sugar control and weight loss.
GoodSupportsHIGH confidence
A systematic review and meta-analysis of RCTs revealed that GLP-1 receptor agonists reduced MACE by 14% and also reduced all-cause mortality by 12%, hospital admission for HF by 11%, and the composite kidney outcome by 21%...
Why this rating
Based on a systematic review and meta-analysis of RCTs.
Source
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Chengxu Ma et al. · Cardiovascular Diabetology · 2022
DOI 10.1186/s12933-022-01516-6
narrative_reviewCited 439×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors reduce major adverse cardiovascular events (MACE) by 11% and heart failure hospitalization by 23% in patients with type 2 diabetes and established cardiovascular disease.Good
- Metformin reduces all-cause mortality by 36% and heart attack incidence by 39% in overweight patients with newly diagnosed type 2 diabetes without established cardiovascular disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →